Alpelisib 150mg Tablets

Alpelisib 150mg Tablets represent a pioneering advancement in the field of precision oncology, specifically engineered for the treatment of advanced breast cancer driven by specific genetic alterations. Pharmacologically, this medication is classified as a kinase inhibitor that functions as a phosphatidylinositol-3-kinase (PI3K) inhibitor. It is the first therapy of its kind to demonstrate a clinically meaningful benefit for patients with this specific mutation profile.

The drug works by targeting the PI3K signaling pathway, a crucial network within cells that regulates metabolism, growth, proliferation, and survival. In many types of cancer, particularly breast cancer, a gene known as PIK3CA can become mutated. This mutation acts like a “stuck gas pedal,” causing the PI3K-alpha (PI3Kα) isoform to become hyperactive. This hyperactivity drives the cancer cells to divide uncontrollably and creates resistance to standard hormonal therapies.

Alpelisib 150mg Tablets bind directly to this overactive PI3Kα enzyme. By blocking its activity, the medication cuts off the downstream signaling to AKT and mTOR. This inhibition deprives the tumor cells of the growth signals they rely on.

Crucially, this mechanism helps to restore the cancer’s sensitivity to endocrine (hormonal) therapy. When used in combination, it creates a dual blockade that is significantly more effective at inducing tumor cell death than hormonal therapy alone. This targeted approach spares patients from the broader toxicity associated with non-selective chemotherapy, focusing instead on the specific molecular driver of their disease.

Indications / Uses of Alpelisib 150mg Tablets

Alpelisib 150mg Tablets are indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The prescription of this medication is strictly guided by the genetic characteristics of the tumor. Specific clinical indications include:

• PIK3CA-Mutated Disease: Indicated specifically for patients whose tumors harbor a PIK3CA mutation. This must be confirmed by an FDA-approved diagnostic test using either a tissue biopsy or a liquid biopsy (blood plasma). Approximately 40% of HR+/HER2- breast cancers carry this mutation.
• Combination Therapy: It is prescribed to be taken in combination with fulvestrant, an endocrine therapy. This combination is used for patients who have experienced disease progression either during or after completing an endocrine-based regimen.
• Overcoming Resistance: The medication is used to overcome resistance to aromatase inhibitors, providing a vital second-line or subsequent option for controlling metastatic disease.
• Metastatic Management: It is designed for the long-term management of advanced cancer, aiming to delay disease progression and maintain quality of life.

Key Features

• Isoform-Specific Inhibition: Unlike pan-PI3K inhibitors that target all forms of the enzyme (which can lead to severe toxicity), Alpelisib is highly selective for the alpha (α) isoform. This specificity improves the therapeutic index, allowing for effective tumor suppression with a more manageable safety profile.
• Oral Administration: The medication is formulated as a tablet, typically taken once daily. The 300mg daily dose (usually two 150mg tablets) offers a convenient oral regimen that can be managed at home.
• Biomarker-Driven Precision: The therapy is a prime example of personalized medicine; efficacy is directly linked to the presence of the PIK3CA mutation, ensuring that the right patient receives the right drug.
• Synergistic Efficacy: Clinical trials, such as the SOLAR-1 study, demonstrated that adding Alpelisib to fulvestrant nearly doubled the progression-free survival (PFS) in patients with the mutation compared to fulvestrant alone.
• Restoration of Hormone Sensitivity: By inhibiting the PI3K pathway, the drug helps re-sensitize the tumor to the effects of estrogen blockade.

Storage for Alpelisib 150mg Tablets

To ensure the stability and safety of Alpelisib 150mg Tablets, proper storage conditions are essential. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief temperature excursions are permitted between 15°C and 30°C (59°F to 86°F), which accommodates travel needs.

Keep the tablets in their original blister pack or bottle until it is time to take them. The packaging protects the active ingredient from moisture, which can degrade the drug. Do not store the medication in humid environments like bathrooms or near kitchen sinks.

If the tablets are broken, cracked, or otherwise damaged, they should not be taken. Ensure the container is kept securely out of the reach and sight of children and pets.

Important Note on Alpelisib 150mg Tablets

Treatment with Alpelisib 150mg Tablets requires strict medical supervision due to specific and potentially serious side effects. Hyperglycemia (high blood sugar) is the most critical and common adverse reaction. The PI3K pathway is involved in insulin signaling; blocking it can cause insulin resistance.

Patients must have their fasting blood glucose and HbA1c levels checked before starting treatment and monitored frequently thereafter. Some patients may need to start anti-diabetic medications (such as metformin) to manage blood sugar levels while on therapy.

Severe Hypersensitivity and Rash: Severe skin reactions, including Stevens-Johnson Syndrome (SJS), can occur. A maculopapular rash is common. Healthcare providers often prescribe prophylactic antihistamines to prevent the onset of rash before starting the drug. Patients should report any skin changes immediately.

Diarrhea is another frequent side effect that requires active management with hydration and anti-diarrheal medications.

Food Effect: It is critical to take Alpelisib immediately after a meal. Taking it on an empty stomach significantly reduces how much drug is absorbed, rendering it much less effective.

The drug can cause fetal harm and is not recommended for pregnant women. Females of reproductive potential should use effective contraception during treatment and for one week after the final dose.